Ownership and insider activity for Genenta Science S.p.A. (GNTA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter.
Price
| Price | $0.74 |
| Market Cap | $14M |
| Exchange | NASDAQ |
| Country | IT |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-03-30 | Paracchi Pierluigi | A-Award | 100,000 | $63K |
| 2026-03-30 | Galimi Francesco | A-Award | 20,000 | $13K |
| 2026-03-30 | PARACCHI GIACOMOANTONIO | A-Award | 20,000 | $13K |
| 2026-03-30 | Sharei Armon | A-Award | 20,000 | $13K |
| 2026-03-30 | Mutti Miguel Maria | A-Award | 20,000 | $13K |
| 2026-03-30 | SLANSKY RICHARD B | A-Award | 80,000 | $50K |
| 2026-03-18 | PARACCHI GIACOMOANTONIO | |||
| 2026-03-18 | PARACCHI GIACOMOANTONIO | |||
| 2026-03-18 | Sharei Armon | |||
| 2026-03-18 | Sharei Armon |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $20.1M | $15.5M | $37.2M | $29.8M | $3.7M | $4.6M | $5.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | $15.1M | $8.1M | $22.6M |
| Receivables | 0 | 0 | $1.4M | $1.6M | $2.0M | $1.4M | $1.3M |
| Inventory | -$163491 | $27671 | $76256 | $144689 | 0 | 0 | 0 |
| Total Current Assets | $20.6M | $16.5M | $38.8M | $31.7M | $21.3M | $14.5M | $30.0M |
| Property, Plant & Equipment | 0 | $18971 | $23090 | $111639 | $57033 | $42922 | $22465 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $88 | $53144 | $87800 | 0 |
| Total Assets | $21.3M | $17.5M | $40.0M | $33.4M | $22.3M | $14.8M | $31.9M |
| Accounts Payable | $572440 | $555015 | $189866 | $1.2M | $294975 | $317830 | $1.5M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.5M | $2.3M | $1.1M | $2.2M | $1.7M | $2.1M | $2.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $7.6M |
| Total Liabilities | $2.5M | $2.4M | $1.2M | $2.3M | $1.9M | $2.3M | $10.0M |
| Retained Earnings | -$15.9M | -$21.5M | -$27.0M | -$35.5M | -$47.1M | -$56.1M | -$62.6M |
| Total Equity | $18.9M | $15.2M | $38.9M | $31.1M | $20.4M | $12.5M | $21.8M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | $14600 | $7.6M |
| Net Debt | -$20.1M | -$15.5M | -$37.2M | -$29.8M | -$18.8M | -$12.6M | -$20.5M |
| Working Capital | $18.1M | $14.2M | $37.6M | $29.5M | $19.5M | $12.4M | $27.9M |
Financial Health
| Debt / Equity | 0.35 |
| Current Ratio | 14.16 |
Profitability
| Return on Equity | -36.82% |
| Return on Invested Capital | -21.33% |
| Return on Assets | -19.60% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BRNS · CVM · INMB · IPSC · JUNS · MDCX · MRSN
Explore sector: Healthcare · Biotechnology
More sections of GNTA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks